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ABSTRACT
Background The BCG vaccine is administered to
protect against tuberculosis, but studies suggest there
may also be non-speciﬁc beneﬁcial effects upon the
infant immune system, reducing early non-targeted
infections and atopic diseases. The present randomised
trial tested the hypothesis that BCG vaccination at birth
would reduce early childhood hospitalisation in
Denmark, a high-income setting.
Methods Pregnant women planning to give birth at
three Danish hospitals were invited to participate. After
parental consent, newborn children were allocated to
BCG or no intervention within 7 days of age.
Randomisation was stratiﬁed by prematurity. The primary
study outcome was number of all-cause hospitalisations
analysed as repeated events. Hospitalisations were
identiﬁed using The Danish National Patient Register.
Data were analysed by Cox proportional hazards models
in intention-to-treat and per-protocol analyses.
Results 4184 pregnant women were randomised and
their 4262 children allocated to BCG or no intervention.
There was no difference in risk of hospitalisation up to
15 months of age; 2129 children randomised to BCG
experienced 1047 hospitalisations with a mean of 0.49
hospitalisation per child compared with 1003
hospitalisations among 2133 control children (mean
0.47), resulting in a HR comparing BCG versus no BCG
of 1.05 (95% CI 0.93 to 1.18) (intention-to-treat
analysis). The effect of BCG was the same in children
born at term (1.05 (0.92 to 1.18)) and prematurely
(1.07 (0.63 to 1.81), p=0.94). The effect was also
similar in the two sexes and across study sites. The
results were essentially identical in the per-protocol
analysis and after adjustment for baseline characteristics.
Conclusions BCG vaccination at birth did not reduce
the risk of hospitalisation for somatic acquired disease
until 15 months of age in this Danish study population.
Trial registration number NCT01694108, results.
BACKGROUND
BCG, primary prophylaxis against tuberculosis, is
among the most widely used vaccines globally.1
Randomised controlled trials indicate that the live
attenuated BCG vaccine against tuberculosis may
have beneﬁcial ‘non-speciﬁc’ or ‘heterologous’
effects on the infant immune system, reducing non-
tuberculosis neonatal mortality in low-income set-
tings by reducing severe early infection.2 3 The
association between BCG and childhood morbidity,
primarily atopic disease has been studied with con-
ﬂicting results.4 The only randomised trial so far
among 121 newborns with high risk of atopy
found BCG to be associated with a signiﬁcant
reduction in the use of medication for eczema.5
From 1979, routine BCG vaccination at school
start was gradually discontinued in Denmark due
to low prevalence of tuberculosis. If BCG has bene-
ﬁcial non-speciﬁc effects on health also in high-
income settings, stopping routine BCG may have
deprived children of these beneﬁcial effects. We
therefore conducted a large-scale randomised trial
in Denmark to test the effect of BCG given at birth
on childhood morbidity, including hospitalisation,
infections, atopic disease, growth, development and
immunological indicators. The present paper pre-
sents the effect of BCG on the primary outcome,
all-cause hospitalisation from birth to 15 months of
age. We hypothesised that BCG vaccination at birth
would reduce all-cause hospitalisation by 20%.
METHODS
Setting, study population
The procedures of The Danish Calmette Study were
published in details elsewhere.6 Brieﬂy, pregnant
women planning to give birth at three Danish
What is already known on this topic?
▸ BCG is the primary prophylaxis against
tuberculosis.
▸ BCG is among the most widely used vaccines
globally.
▸ There may be non-speciﬁc beneﬁcial effects of
neonatal BCG vaccination upon the infant
immune system, reducing early infections and
atopic disease.
What this study adds?
BCG vaccination did not reduce the risk of
hospitalisation for acquired somatic disease during
the ﬁrst 15 months of life in a Danish study
population.
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hospitals were invited. Inclusion criteria were gestational age of
32+ weeks, birth weight of 1000+ grams and a signed informed
consent from the parents. Exclusion criteria were maternal intake
of immunomodulating medicine during pregnancy, signs of
severe illness or major malformation in the infant and no
Danish-speaking parent due to concerns about language barrier.
Newborns were allocated 1:1 to standard BCG vaccination with
the Danish strain 1331, or no intervention within 7 days of birth.
The children were allocated 1:1 in permuting blocks of 2-4-6
using an online system. Since in prior studies the strongest non-
speciﬁc effects on mortality have been seen among the smallest
newborns,2 3 the allocation was stratiﬁed by prematurity deﬁned as
gestational age <37 weeks. The allocation was planned stratiﬁed
also by sex and study site; however, by programme error the allo-
cation was stratiﬁed only by prematurity. Parents were not blinded
to allocation since the local inﬂammatory reaction caused by BCG
vaccination could not be mimicked, but the parents were asked not
to disclose if the child had received BCG to keep study staff
blinded during the data collection.
Follow-up
The primary outcome was all-cause hospitalisations. Since the
measles-mumps-rubella vaccine (MMR) may also have non-
speciﬁc effects, follow-up was censored at 15 months of age
where MMR is scheduled in the Danish national vaccination
programme.7 8
All Danish residents have a unique identiﬁcation number,
which was used to obtain information from The Danish National
Patient Register on acquired, somatic all-cause hospitalisation,
including dates of admission and discharge and categorised by the
International Classiﬁcation of Diseases V.10 (ICD10) diagnosis
codes.9 10 Outpatient and emergency department hospital con-
tacts not leading to admission, and hospitalisations starting before
or at the date of randomisation were excluded. Since the study
aimed to examine if BCG reduced acquired somatic morbidity,
diagnostic codes due to administrative procedures, admission to
the maternity ward in connection with the delivery, congenital
and birth-related conditions, psychiatric disease, and injuries were
excluded (ICD10-speciﬁcation in the online supplement).
Figure 1 Flow chart. Data collection of The Danish Calmette Study, by telephone interviews, clinical examinations and health registers.
Percentages in parentheses (): Percentage among the eligible children. Percentages in square brackets []: Percentage among all randomised children.
*Interviews conducted between child age 2–4 months: BCG 98.1% (2089/2129), control 96.8% (2064/2133). #Interviews conducted between child
age 10–14 months: BCG 97.9% (2084/2129), control 96.2% (2052/2133).
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Furthermore, follow-up consisted of telephone interviews and
clinical examinations at 3 months and 13 months of age; sec-
ondary outcomes and adverse events will be published
separately.
Power calculation
Sample size estimates were based on 95% CIs and a 90%
power. Twenty per cent of the child population in Denmark was
expected to be hospitalised during the ﬁrst 15 months of life.11
To detect a 20% reduction in hospitalisations during the ﬁrst
15 months of life, 3972 newborns needed to be included. We
expected a very small loss to follow-up in the registry-based
studies and aimed to include approximately 4300 newborns.
Statistics
Cox proportional hazards models were used to estimate the HR
of all-cause hospitalisation between the BCG and control
groups. Adjustment for recurrent hospitalisations for each child
was done using robust SEs for the estimated HRs. The results
are presented as HRs with 95% CIs and corresponding p values.
The children were censored at migration, 15 months of age or
death, whichever came ﬁrst. The analyses were stratiﬁed by pre-
maturity in accordance with the randomisation procedure. In the
main ‘intention-to-treat (ITT) analysis’ hospitalisations within
the period from randomisation to 15 months of age were ana-
lysed according to randomisation group. We also conducted a
‘per-protocol (PP) analysis’ in which children who did not follow
the allocation were excluded and hospitalisations from time since
vaccination for the BCG group and time since randomisation for
controls was included. Curves for mean number of hospitalisa-
tions by randomisation arm as a function of time since random-
isation were estimated using the Nelson-Aalen method. Further,
we tested the effect of BCG on time to ﬁrst hospitalisation.
Secondary analyses
Using Cox models, we tested if adjustment for baseline
characteristics changed the estimates. Since previous studies
indicate that the non-speciﬁc effects of one vaccine may be
modiﬁed by a subsequent different vaccination,12 follow-up was
divided into 0–2 months (0–89 days) while the children had
received BCG or nothing, and 3–15 months (90–456 days)
when the children should have received one to three doses of
diphtheria, tetanus, acellular pertussis, polio, Haemophilus
inﬂuenzae type b and Streptococcus pneumonia vaccine accord-
ing to the routine vaccination programme.8
We also estimated potential effect modiﬁcation by caesarean
section, administration of antibiotics to the mother during deliv-
ery, birth weight <2500 g, ≥one sibling, atopic disposition, vac-
cination ≤2 days of age, maternal BCG vaccination and by the
two vaccine batches used in the study. The analysis by batch was
adjusted for calendar months.
All analyses were performed using Stata V.13 (StataCorp LP,
Texas, USA).
RESULTS
Randomisation and baseline
At the three hospitals 16 521 pregnant women were invited. No
response was given by 6148 families, and 6189 families were
excluded primarily because they declined participation after being
informed verbally about the study (ﬁgure 1). Four thousand one
hundred and eighty-four pregnant women were randomised and
their 4262 children allocated to BCG or no intervention
(ﬁgure 1). Baseline characteristics with potential inﬂuence on
childhood morbidity did not differ between the two allocation
groups except for ethnicity other than Danish and smoking, which
were more common in families of control children (table 1).
The study population was characterised by a large proportion
of highly educated parents, with a high prevalence of atopic
diseases.
Treatment assignments and crossovers
Two thousand one hundred and twenty-nine children were ran-
domised to receive BCG and 2133 children to the control
group. Eleven children randomised to the BCG group did not
receive the BCG vaccine and 36 children randomised to the
control group received the BCG vaccine on their own initiative
leaving 2118 children allocated to BCG and BCG-vaccinated
groups and 2097 children randomised to control and not vacci-
nated groups in the PP analysis.
Table 1 Baseline characteristics by allocation among 4184 Danish
mothers in The Danish Calmette Study
BCG (N=2095)
n (%*) (NA)
Control
(N=2089)
n (%) (NA)
Male sex† 1092 (52.1) (0) 1104 (52.9) (0)
Prematurity (GA<37 weeks) 61 (2.9) (0) 60 (2.9) (0)
Randomisation site (0) (0)
Rigshospitalet 751 (35.9) 780 (37.3)
Hvidovre 730 (34.8) 719 (34.4)
Kolding 614 (29.3) 590 (28.4)
Caesarean section 411 (19.6) (0) 442 (21.2) (0)
Antibiotics during delivery‡ 333 (15.9) (0) 358 (17.1) (0)
Singletons 2061 (98.4) (0) 2046 (97.9) (0)
Twins 34 (1.6) 42 (2.0)
Triplets 0 1 (0.0)
Birth weight in grams (mean±SD) 3519±493 (0) 3523±494 (0)
Child <1 day of age at randomisation 1006 (48.0) (0) 1000 (47.9) (0)
Maternal age in years at birth
(mean±SD)
32.0±4.6 (0) 31.9±4.4 (0)
≥1 parent of ethnicity other than
Danish
376 (18.1) (14) 458 (22.1) (15)
Maternal education (7) (6)
No higher education 460 (22.0) 435 (20.9)
Short/medium higher education 935 (44.8) 939 (45.1)
Long higher education 693 (33.2) 709 (34.0)
Parents living together 1984 (94.9) (4) 1984 (95.0) (0)
Mother BCG vaccinated 364 (17.6) (27) 353 (17.2) (41)
≥1 older sibling 887 (42.4) (1) 843 (40.4) (2)
Atopic disposition§
Maternal atopic disease 839 (41.6) (80) 809 (40.3) (83)
Paternal atopic disease 717 (38.2) (217) 708 (37.7) (209)
Parental atopic disease 1265 (65.7) (168) 1243 (64.1)
(151)
Siblings with atopic disease 275 (13.3) (30) 252 (12.2) (23)
Smoking during pregnancy
Maternal 203 (9.7) (1) 212 (10.2) (1)
Paternal 388 (18.9) (38) 458 (22.2) (31)
*Percentage among families where the information was available.
†The sex of the first child in multiple births.
‡Antibiotics to the mother during elective caesarean section were administered after
disconnection of the umbilical cord at the Kolding site and before the umbilical cord
was disconnected at Rigshospitalet and Hvidovre sites.
§Atopic disposition defined as physician-diagnosed atopic eczema, asthma, allergic
rhinoconjunctivitis or food allergy.
GA, gestational age; NA, not available (number of families without information on
the specified variable).
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Primary outcome: risk of all-cause hospitalisation
The rate of follow-up was 100% (ﬁgure 1). Until 15 months of
age, the 2129 children randomised to BCG experienced a total
of 1047 hospitalisations, the mean hospitalisation per child
being 0.49; compared with 1003 hospitalisations among 2129
children randomised to control, the mean hospitalisation per
control child being 0.47. Hence, there was no difference in
number of hospitalisations from randomisation to 15 months of
age in the ITTanalysis (table 2 and ﬁgure 2).
There was no effect modiﬁcation by prematurity, sex or study
site (table 2); however, the rate of hospitalisation was lower at the
Kolding site where short acute admissions were classiﬁed as out-
patient consultations. The results were essentially identical in the
PP analysis (table 2). If the outcome was deﬁned as time to ﬁrst
hospitalisation instead of recurrent hospitalisations, the HRs were
1.01 (0.91 to 1.13) (ITT) and 1.02 (0.92 to 1.14) (PP), respect-
ively. The inclusion in the analysis of children from multiple
births as clusters did not change the estimates (data not shown).
Table 2 Number of hospitalisations among 4262 Danish children by allocation to BCG vaccination at birth or control group (no intervention)
Intention-to-treat
analysis*
Allocated to BCG.
Number of
hospitalisations
(n†) (mean‡)
Allocated to
control.
Number of
hospitalisations
(n†) (mean‡)
HR,
crude 95% CI
p Value of effect
modification
between the
groups
HR,
adjusted§ 95% CI
p Value of effect
modification
between the
groups
All n=4262 1047 (2129) (0.49) 1003 (2133) (0.47) 1.05 0.93 to 1.18 1.05 0.93 to 1.20
Prematurity 0.94 0.14
Premature¶ n=144 62 (71) (0.87) 59 (73) (0.81) 1.07 0.63 to 1.81 1.56 0.91 to 2.66
Mature n=4118 985 (2058) (0.48) 944 (2060) (0.46) 1.05 0.92 to 1.18 1.03 0.91 to 1.17
Sex 0.44 0.48
Male n=2241 604 (1104) (0.55) 570 (1137) (0.50) 1.09 0.93 to 1.29 1.09 0.93 to 1.29
Female n=2021 443 (1025) (0.43) 433 (996) (0.44) 0.99 0.83 to 1.20 1.00 0.82 to 1.21
Study site 0.20 0.12
Rigshospitalet n=1567 383 (764) (0.50) 391 (803) (0.49) 1.04 0.85 to 1.28 1.02 0.82 to 1.27
Hvidovre n=1470 451 (738) (0.61) 384 (732) (0.53) 1.16 0.96 to 1.41 1.21 0.99 to 1.47
Kolding n=1225 213 (627) (0.34) 228 (598) (0.38) 0.88 0.69 to 1.12 0.87 0.68 to 1.11
Per-protocol
analysis**
BCG vaccinated.
Number of
hospitalisations
(n†) (mean‡)
Control group.
Number of
hospitalisations
(n†) (mean‡) HR 95%-CI
p Value of effect
modification
between the
groups
HR,
adjusted§ 95%-CI
p Value of effect
modification
between the
groups
All n=4215 1044 (2118) (0.49) 979 (2097) (0.47) 1.06 0.93 to 1.19 1.06 0.93 to 1.20
Prematurity 0.90 0.13
Premature¶ n=143 62 (71) (0.87) 57 (72) (0.79) 1.09 0.64 to 1.87 1.60 0.92 to 2.77
Mature n=4071 982 (2047) (0.48) 922 (2025) (0.45) 1.05 0.93 to 1.20 1.04 0.91 to 1.18
Sex 0.35 0.39
Male n=2214 604 (1096) (0.55) 554 (1118) (0.50) 1.11 0.95 to 1.31 1.11 0.94 to 1.31
Female n=2000 440 (1022) (0.43) 425 (979) (0.43) 0.99 0.82 to 1.19 1.00 0.82 to 1.21
Study site 0.28 0.17
Rigshospitalet n=1543 383 (761) (0.50) 379 (782) (0.49) 1.05 0.85 to 1.30 1.03 0.83 to 1.28
Hvidovre n=1456 448 (734) (0.61) 379 (722) (0.53) 1.16 0.96 to 1.41 1.20 0.98 to 1.46
Kolding n=1215 213 (623) (0.34) 221 (593) (0.37) 0.91 0.71 to 1.15 0.89 0.70 to 1.14
Intention-to-treat and per-protocol analyses.
*All children randomised were followed from randomisation to 15 months of age and analysed according to randomisation group.
†Number of children.
‡Mean hospitalisation per child.
§Adjusted for baseline characteristics (sex, prematurity, study site, caesarean section, antibiotics during delivery, multiple birth, birth weight, child age at randomisation, maternal age,
parental ethnicity (≥1 parent of ethnicity other than Danish), maternal education, parents living together, maternal BCG (by maternal recall), siblings, maternal atopy and maternal
smoking during pregnancy).
¶Prematurity defined as birth before 37 weeks of gestation.
**Children having received the BCG vaccine but randomised to control group, or vice versa were excluded. The remaining children were followed from time since vaccination for the
BCG group and time since randomisation for control children.
Figure 2 Estimated mean number of all-cause hospitalisations per
child for children randomised to BCG or no BCG.
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Table 3 Secondary analysis
Intention-to-treat analysis
Allocated to BCG (n=2129).
Number of hospitalisations (n)
(mean*)
Allocated to control (n=2133).
Number of hospitalisations (n)
(mean*) HR, crude 95% CI
p Value of effect
modification
between the
groups HR, adjusted† 95% CI
P Value of effect
modification
between the groups
Caesarean section n=892 239 (428) (0.56) 281 (464) (0.61) 0.91 0.72 to 1.16 0.19 0.98 0.77 to 1.26 0.53
No n=3370 808 (1701) (0.48) 722 (1669) (0.43) 1.10 0.95 to 1.27 1.08 0.93 to 1.25
Antibiotics during delivery n=712 233 (340) (0.69) 213 (372) (0.57) 1.22 0.92 to 1.61 0.24 1.23 0.92 to 1.65 0.25
No n=3550 814 (1789) (0.46) 790 (1761) (0.45) 1.01 0.88 to 1.16 1.01 0.88 to 1.16
Birth weight <2500 g n=123 46 (61) (0.75) 53 (62) (0.86) 0.91 0.51 to 1.62 0.62 1.05 0.59 to 1.88 0.99
No n=4139 1001 (2068) (0.48) 950 (2071) (0.46) 1.05 0.93 to 1.19 1.05 0.93 to 1.20
≥1 older sibling n=1761 427 (905) (0.47) 406 (856) (0.47) 0.98 0.93 to 1.28 0.40 0.97 0.80 to 1.17 0.28
No n=2498 619 (1223) (0.51) 596 (1275) (0.47) 1.09 0.81 to 1.19 1.11 0.94 to 1.32
Disposition
Parental atopic disease n=2558 664 (1286) (0.52) 614 (1272) (0.48) 1.07 0.91 to 1.24 0.26 1.08 0.92 to 1.27 0.36
No n=1379 298 (675) (0.44) 340 (704) (0.48) 0.91 0.73 to 1.14 0.95 0.76 to 1.19
Siblings with atopic disease
n=532
149 (276) (0.54) 123 (256) (0.48) 1.11 0.79 to 1.58 0.68 1.16 0.81 to 1.66 0.57
No n=3667 882 (1823) (0.48) 873 (1854) (0.47) 1.03 0.90 to 1.17 1.04 0.91 to 1.19
Season‡
Winter n=1047 324 (522) (0.62) 301 (525) (0.57) 1.08 0.85 to 1.37 0.46 1.08 0.85 to 1.38 0.43
Spring n=981 246 (488) (0.50) 205 (493) (0.42) 1.22 0.95 to 1.55 1.24 0.96 to 1.59
Summer n=1057 192 (530) (0.36) 199 (527) (0.38) 0.96 0.74 to 1.25 0.97 0.74 to 1.28
Autumn n=1177 285 (589) (0.48) 298 (588) (0.51) 0.96 0.76 to 1.20 0.95 0.75 to 1.20
Mother BCG vaccinated n=740 168 (372) (0.45) 206 (368) (0.56) 0.81 0.60 to 1.09 0.05 0.83 0.60 to 1.13 0.09
No n=3453 871 (1730) (0.50) 775 (1723) (0.45) 1.12 0.98 to 1.28 1.11 0.97 to 1.28
Per-protocol analysis
BCG vaccinated (n=2118).
Number of hospitalisations
(n) (mean*)
Control group (n=2097).
Number of hospitalisations
(n) (mean*) HR, crude 95% CI
p Value of effect
modification
between the groups HR, adjusted† 95% CI
P Value of effect
modification
between the groups
Caesarean section n=881 236 (424) (0.56) 276 (457) (0.60) 0.96 0.72 to 1.16 0.17 0.98 0.76 to 1.25 0.45
No n=3334 808 (1694) (0.48) 703 (1640) (0.43) 1.12 0.97 to 1.29 1.09 0.94 to 1.26
Antibiotics during delivery n=701 233 (339) (0.69) 209 (362) (0.58) 1.21 0.92 to 1.60 0.29 1.22 0.90 to 1.64 0.30
No n=3514 811 (1779) (0.46) 770 (1735) (0.44) 1.02 0.89 to 1.17 1.02 0.89 to 1.18
Birth weight <2500 g n=122 46 (61) (0.75) 53 (61) (0.87) 0.89 0.50 to 1.60 0.56 1.04 0.58 to 1.87 0.95
No n=4093 998 (2057) (0.49) 926 (2036) (0.46) 1.07 0.94 to 1.21 1.06 0.93 to 1.21
≥1 older sibling n=1751 427 (901) (0.47) 498 (850) (0.47) 1.00 0.83 to 1.21 0.46 0.98 0.81 to 1.19 0.32
No n=2461 616 (1216) (0.51) 580 (1245) (0.47) 1.10 0.93 to 1.29 1.12 0.94 to 1.32
Atopic disposition
Parental atopic disease n=2530 664 (1278) (0.52) 599 (1252) (0.48) 1.08 0.93 to 1.26 0.20 1.10 0.94 to 1.29 0.27
No n=1361 295 (672) (0.44) 332 (689) (0.48) 0.89 0.73 to 1.13 0.69 0.94 0.75 to 1.18 0.59
Siblings with atopic disease n=528 149 (274) (0.54) 122 (254) (0.48) 1.12 0.79 to 1.59 1.16 0.81 to 1.67
No n=3634 879 (1814) (0.49) 850 (1820) (0.47) 1.04 0.91 to 1.19 1.05 0.91 to 1.20
Season‡
Winter n=1035 321 (519) (0.62) 299 (516) (0.58) 1.07 0.84 to 1.36 0.48 1.06 0.83 to 1.35 0.44
Spring n=970 246 (488) (0.50) 196 (482) (0.41) 1.24 0.97 to 1.59 1.26 0.98 to 1.63
Summer n=1042 192 (525) (0.37) 195 (517) (0.38) 0.97 0.74 to 1.26 0.98 0.74 to 1.29
Autumn n=1168 285 (586) (0.49) 289 (582) (0.50) 0.98 0.75 to 1.24 0.97 0.77 to 1.23
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Secondary analyses
Adjustment for all baseline characteristics essentially did not
change the estimates (see table 2 and 3), the HR of hospital-
isation was 1.05 (0.93 to 1.20) for children randomised to
BCG. For children randomised to BCG, the risk of hospi-
talisation was 0.98 (0.83 to 1.16) until 3 months and 1.09
(0.94 to 1.27) after 3 months of age. No statistically signiﬁ-
cant effect modiﬁcation by caesarean section, administra-
tion of antibiotics to the mother during vaginal delivery, birth
weight <2500 g, ≥1 sibling, atopic disposition, age at vaccin-
ation ≤2 days, maternal BCG vaccination and BCG vaccine
batch was observed (table 3). However, a tendency towards
protection against hospitalisation was observed among BCG-
vaccinated children whose mother was also BCG vaccinated
(table 3).
DISCUSSION
We hypothesised that BCG vaccination at birth would have non-
speciﬁc beneﬁcial effects and reduce overall childhood hospital-
isation for somatic acquired disease (injuries excluded) from
birth to 15 months of age by 20% in the high-income setting of
Denmark. We were not able to conﬁrm this.
Strengths and weaknesses
The strengths of the present study lie in the randomised clin-
ical multicentre trial design with adequate power. Data on the
primary study outcome, all-cause hospitalisation, were col-
lected independently of the study, decreasing the risk of bias.
All participants could be followed up through the public
registers.
The study may be limited by our choice of all-cause hospital-
isation as primary outcome, which was chosen because of its
potentially high impact on public health and because this
outcome included both hospitalisation-requiring infections and
severe manifestations of atopic disease. Given the high incidence
of hospitalisations, this outcome, however, may not have been
speciﬁc enough to detect a potential beneﬁcial immune-training
effect of BCG.
Comparison with other studies
In low-income settings, two randomised controlled trials among
low birthweight children found BCG to reduce non-tuberculosis
mortality until 6 months of age, in particular neonatal sepsis
and respiratory infections.2 3 Recent immunological studies have
provided a potential mechanism by showing that BCG induces
trained innate immunity through epigenetic reprogramming of
monocytes,13 14 which was still present 12 months after
BCG.13 15 In Guinean babies, BCG was associated with increased
responses to heterologous innate stimulation.16
There may be other explanations for the lack of effect of
BCG on all-cause hospitalisation in Denmark.
First, in a system with free healthcare, hospitalisation for
acquired somatic disease may not represent a sufﬁciently speciﬁc
measure of disease. A high level of parental concern in combin-
ation with a low professional threshold for hospitalisation of
young infants is likely to have inﬂated the hospitalisation rate.
The rate of all-cause hospitalisation was 50% higher than
expected.
Second, there are obvious differences in exposure to infection
between Denmark and the low-income settings where the bene-
ﬁcial non-speciﬁc effects of BCG on mortality have been
observed. The majority of children in the present study had no
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siblings, thus, presumably the exposure to infections was limited
until they started day care around 1 year of age.
Third, we previously found that maternal immunity may also
be of importance to the non-speciﬁc response to measles vaccin-
ation in the child;17 we therefore also asked whether the
mothers in The Danish Calmette Study had been BCG vacci-
nated. In low-income settings the majority of mothers will have
been BCG vaccinated, whereas in our study only 17% of the
mothers had been BCG vaccinated, because BCG was discontin-
ued in the early 1980s. That early exposure may be of import-
ance to the child’s response to BCG was also indicated by two
studies comparing cytokine responses after BCG in UK and
Malawi infants, and ﬁnding signiﬁcant differences, which were
ascribed to exposure very early, in utero, or within the ﬁrst few
months of life.18 19 Further, it has been shown that foetal T
helper cells can be sensitised to mycobacterial puriﬁed protein
derivative in utero.20 In agreement with this, in a preplanned
secondary analysis of hospitalisations for infection within the
present trial, a signiﬁcant beneﬁcial effect of BCG among chil-
dren of BCG-vaccinated mothers was observed (personal com-
munication, Stensballe LG, Greisen G, Jeppesen DL, et al. The
effect of BCG vaccination at birth on risk of hospitalization for
infection in Denmark. A randomized clinical multicenter trial.
2015. Unpublished work). If maternal exposure to BCG or
mycobacteria is essential for the development of beneﬁcial non-
speciﬁc effects of BCG, this may explain the beneﬁcial effect of
BCG observed in low-income countries but not overall in the
present study.
Fourth, genetics differ between the populations of West Africa
and Denmark;21–23 however, the inﬂuence of this is not clear
and it should be noted that others have found evidence of bene-
ﬁcial effects of BCG in Denmark.24
CONCLUSIONS
BCG vaccine at birth did not decrease the risk of hospitalisation
for somatic acquired disease until 15 months of age in our high-
income setting.
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